Background: We undertook a randomized phase II trial to test whether the addition of paclitaxel (Taxol) to the cisplatin and ifosfamide (IP) combination could improve objective response (OR) rate, progression-free survival (PFS) and overall survival (OS) in patients with recurrent or metastatic cancer of the uterine cervix. Results: A modest increase in neurotoxicity was observed with the triplet combination. OR rate was significantly higher in the ITP group (59% versus 33%, P = 0.002). Median PFS was 7.9 and 6.3 months for patients in the ITP and IP arms, respectively (P = 0.023). Median OS was 15.4 months and 13.2 months in the ITP and IP arms, respectively (P = 0.048). In multivariate analysis, the triplet yielded a hazard ratio of 0.70 for relapse or progression (P = 0.046) and 0.75 for death (P = 0.124) compared with the doublet.
introduction
Carcinoma of the uterine cervix is the second most common cancer in women worldwide and one of the most important causes of cancer-related death, especially in developing countries [1] . Despite the declining mortality rate from cervical cancer observed through the last decade [2] , advanced or recurrent disease remains a major cause of death [3] . For these patients, prognosis is poor with 1-year survival rates ranging from 15% to 20% [4] .
Single-agent cisplatin has been considered the standard systemic treatment for advanced squamous cell carcinoma of the uterine cervix for more than two decades, based on the results of a phase II trial conducted by the Gynecologic Oncology Group (GOG) that demonstrated a 44% objective response (OR) rate in previously untreated patients [5] .
Subsequent studies established the dose of 50 mg/m 2 , every 3 weeks, as the optimal regimen combining low toxicity with comparable efficacy to that of more intensified regimens [6, 7] . During the 1990s, the identification of other chemotherapeutic drugs with single-agent activity, including mitomycin C [2] , ifosfamide [8] [9] [10] , topotecan [11, 12] , paclitaxel [13] [14] [15] , gemcitabine [16] and vinorelbine [17, 18] , led to the concept that a combination of these drugs with cisplatin could enhance clinical efficacy. Indeed, three phase III trials established the role of combination chemotherapy showing a progression-free survival (PFS) advantage for the combinations of cisplatin with either ifosfamide [19] or paclitaxel (GOG 0169) [20] and an advantage in both PFS and overall survival (OS) for the cisplatin-topotecan combination (GOG 0179) [21] .
More recently, the combination of multiple agents in advanced cervical cancer has emerged as an appealing approach. In a recent study from European Organisation for Research [23] . Based on these data, in 1999, we initiated a randomized phase II trial to test whether the addition of paclitaxel to the cisplatin and ifosfamide combination could improve OR rate, PFS and OS in women with recurrent or metastatic carcinoma of the uterine cervix and to compare toxic effects between the triplet and the doublet.
patients and methods
patient selection
Patients were eligible for the study if they had histologically documented primary metastatic or recurrent carcinoma of the uterine cervix no longer amenable to surgery and/or radiation therapy and had not received chemotherapy for advanced disease with the exception of prior cisplatin administration given as radiation sensitizer. Other eligibility requirements included ECOG PS of zero to two, one or more lesions measurable in perpendicular diameters by imaging studies, neutrophil count ‡1500/ll, platelet count ‡100 000/ll, creatinine clearance ‡ 50 ml/min, serum bilirubin <2.0 mg/dl and alanine aminotransferase and aspartate aminotransferase levels less than twice the institutional upper limit of normal, 3 weeks from prior surgery and 4 weeks from radiation. The study was approved by the HeCOG Protocol Review Committee and informed consent was obtained from all patients before study entry in all eight institutions that participated in the trial. Patients were excluded if they had brain metastases, active infection, serious concurrent medical illnesses and preexisting clinically significant peripheral neuropathy by any cause.
evaluation
Before study entry, all patients underwent a complete physical and gynecologic examination, assessment of PS, complete blood cell (CBC) count, liver and kidney function tests, pelvic and abdominal computed tomography (CT) and chest X-ray with CT of the chest in cases of lung or mediastinal lymph node metastases. Imaging of the brain and the bones were carried out if clinically indicated. Magnetic resonance imaging of the pelvis was carried out in cases of pelvic recurrence in patients with equivocal findings on CT scans. During treatment, CBC counts and creatinine and liver function tests were repeated on days 10 and 28 of each cycle. Physical examination and safety evaluations were conducted before each cycle. Response to treatment was assessed every other cycle by repeating all abnormal imaging modalities. Assessment of treatment outcome was blinded to the treatment group assignment.
treatment plan
Chemotherapy was administered on an outpatient basis every 28 days and consisted (arm A) of ifosfamide given at a dose of 1500 mg/m 2 , i.v. over 1 h, on days 1-3, diluted in 1000 ml of 0.9% saline. Sodium-2-mercaptoethane sulfate (MESNA) was given at a dose of 300 mg/m 2 , i.v. over 15 min, before each dose of ifosfamide. The same dose of MESNA was given orally at home 4 and 8 h after the administration of ifosfamide. On day 2, before ifosfamide administration, patients received 900 ml of 0.9% saline with 100 ml of 20% mannitol over 1 h, immediately followed by cisplatin 70 mg/m 2 diluted in 1000 ml of 0.9% saline and infused over 3 h. Subsequently, the patients received an additional liter of normal saline with potassium and magnesium to minimize cisplatin-induced renal toxicity. Arm B consisted of the same regimen as arm A, but on day 1 of each cycle paclitaxel (Taxol, Bristol-Myers Squibb, New York, NY) 175 mg/m 2 diluted in 500 ml of 0.9% saline was infused i.v. over 3 h before ifosfamide administration. All patients in arm B received a pretreatment regimen designed to abrogate allergic reactions to paclitaxel. Granulocyte colony-stimulating factor (G-CSF) was systematically administered s.c. from days 7 to 11 of each cycle at a dose of 5 lg/kg/day in both arms. Since chemotherapy courses were administered every 28 days instead of the usual 21-day schedule, cisplatin dose was adjusted to 70 mg/m 2 instead of the standard 50 mg/m 2 dosing, in order to maintain equivalent dose intensity (DI) of the drug. Chemotherapy was administered for a target of six cycles but was discontinued in cases of progressive disease (PD) or unacceptable toxicity. The doses of paclitaxel and ifosfamide were reduced by 25% if febrile neutropenia or thrombocytopenia grade 3 or 4 occurred, but the dose of cisplatin was not altered. In case of neurotoxicity higher than grade 2, treatment was delayed by 1 or 2 weeks and subsequent paclitaxel doses were reduced by 25%. Cisplatin was reduced by 50% for a creatinine level more than two times baseline and withheld for a creatinine level more than three times baseline. If treatment was delayed by 3 weeks or more, for any reason, the patient was taken off the study.
definition of response and toxicity
World Health Organisation criteria for response and toxicity were used [24] . One dose of therapy was considered adequate for response. A complete response (CR) required disappearance of all clinically detectable disease for at least 4 weeks. A partial response (PR) required >50% reduction in the product of the two largest perpendicular dimensions of bidimensionally measurable lesions for at least 4 weeks. PD required >25% increase in the product of the two largest perpendicular dimensions of bidimensionally measurable lesions. All other cases not meeting the criteria for CR, PR or PD were considered to have stable disease (SD).
dose delivery analysis
We used the method described by Hryniuk and Goodyear [25] . A value for received dose intensity (DI) was calculated by dividing the cumulative treatment dose by the number of treatment weeks. In order to adjust for patients who had received different numbers of cycles, one treatment interval was added for each patient following a rationale previously described by Coppin [26] .
statistical considerations
The primary end point of the study was OR. PFS, OS and toxicity were secondary end points. The sample size was calculated on the assumption that a 625% difference in response rate, to a baseline of 30%, existed between the two groups. For an alpha of 0.05 and a power of 0.80, a sample of 154 patients was required. Categorical variables were summarized as count and corresponding percentage and compared using the Fisher's exact test, while continuous variables were summarized as median and range and compared using the Mann-Whitney test. All tests were two sided. Survival was estimated from the initiation of treatment to the date of last follow-up or until the patient's death. PFS was calculated from the initiation of treatment to the first documented progression of the disease. At the calculation of PFS, deaths due to the disease without previous documentation of disease progression were considered as events. The Kaplan-Meier method was used to estimate the time-to-event distributions.
Cox regression analysis was used to estimate the hazard ratio (HR) of the allocated treatment. In order to account for potentially important prognostic factors, Cox regression analysis was carried out for OS and PFS. PS ( ‡1 versus 0), age (as a continuous variable), interval from diagnosis (£6 months versus >6 months), relapse inside a previously irradiated area (yes/ no), prior cisplatin administration (yes/no) and group of randomization [ifosfamide, paclitaxel and cisplatinum (ITP)/cisplatin and ifosfamide (IP)] were included in the models. The backwards selection process, using the maximum likelihood procedure, was used in order to conclude on the Annals of Oncology original article independent prognostic factors for patients' OS and PFS. Analysis was carried out following the modified intention-to-treat principle, i.e. including all eligible patients.
results

patient characteristics
From September 1999 to January 2006, 153 patients with recurrent or metastatic cervical carcinoma were accrued to the study. Among them, four were considered to be ineligible for the following reasons: prior chemotherapy for recurrent or metastatic disease (three patients) and second primary neoplasm (one patient). The flowchart of the study is shown in Figure 1 . The main characteristics of the patients and their tumors are summarized in Table 1 .
treatment characteristics
Treatment characteristics including DI and relative dose intensity (RDI) for each agent are shown in Table 2 . The target of at least six consecutive chemotherapy cycles was achieved in 54% and 63% of patients who received the IP and the ITP regimens, respectively. Main reasons for discontinuation of treatment were disease progression and patient refusal. There was no statistically significant difference regarding DI and RDI for both cisplatin and ifosfamide when the two arms of the study were compared.
response and survival
Following the modified intention-to-treat analysis, 73 and 76 patients in the IP and ITP arm, respectively, were assessable for response. We observed eight CRs in the IP arm [11%; 95% confidence interval (CI) 5% to 20%] compared with 19 CRs in the ITP arm (25%; 95% CI 16% to 36%) and this difference was statistically significant (P = 0.033). Moreover, the number of patients achieving a PR was higher in the ITP group (34% versus 22%, 95% CI 24% to 46% and 13% to 33%, respectively), but this difference did not reach statistical significance (P = 0.105). Overall, the number of patients achieving an OR was significantly higher in the ITP group (59% versus 33%, 95% CI 47% to 70% and 22% to 45%, respectively, P = 0.002).
Median follow-up of the study population was 57.3 months (range 4-96 months). There were no patients lost to followup. Figure 2A illustrates PFS in both arms. Median PFS was 6.3 months (95% CI 4.3-8.2 months) for patients treated with the IP regimen and 7.9 months (95% CI 6.1-9.8 months) for those treated with ITP (P = 0.023). Figure 2B illustrates OS in both arms. Median OS was 13.2 months (95% CI 10.9-15.5 months) for patients in the IP arm and 15.4 months (95% CI 8.6-22.3 months) for patients in the ITP arm, respectively (P = 0.048). In univariate Cox analysis, the unadjusted HR for progression and death were 0.68 (95% CI 0.48-0.95; P = 0.024) and 0.70 (95% CI 0.50-1.0; P = 0.049), respectively, favoring the ITP arm.
In univariate analysis, the most important prognostic factors were PS at diagnosis (HR = 2.40, 95% CI 1.68-3.42, P < 0.001 for OS and HR = 2.63, 95% CI 1.85-3.74, P < 0.001 for PFS) and age as a continuous variable (HR = 1.02, 95% CI 1.01-1.04, P = 0.003 for OS and HR = 1.02, 95% CI 1.01-1.04, P = 0.004 for PFS). Of note, the HRs for progression and death for patients who relapsed inside a previously irradiated field were 1.27 (95% CI 0.90-1.78, P = 0.167) and 1.34 (95% CI 0.95-1.91, P = 0.099), respectively. Prior cisplatin administration and time interval (£6 months versus >6 months) from initial diagnosis to the time of disease recurrence did not have any impact on patients' outcome. In the multivariate model, only PS at diagnosis (0 versus 1 or 2), treatment regimen (ITP versus IP) and age at diagnosis as a continuous variable maintained predictive significance for PFS and OS (Table 3 ). The HR for relapse or death increased by 2% per year of age. The final multivariate model was not modified when relapse inside or outside a previously irradiated field was included as a variable in the analysis.
toxicity
Adverse events are reported in Table 4 . There were no significant differences between the two arms apart from stomatitis and neurotoxicity. Rate of any grade stomatitis was significantly higher in the ITP arm (0% versus 10%, P = 0.007). Also, the rate of any grade neurotoxicity was significantly higher in the same arm (11% versus 43%, P < 0.001). There were two cases of severe renal impairment requiring hemodialysis in the IP group, probably related to cisplatin administration. One case of stroke and one case of pulmonary embolism in the ITP arm were also reported. No The optimal chemotherapy regimen for advanced cervical cancer has not been determined yet. We have previously demonstrated the safety and efficacy of the paclitaxel and cisplatin combination [27] and more recently the efficacy and feasibility of the ITP triplet in a phase II study conducted by HeCOG [23] . In the current study, we evaluated whether the addition of paclitaxel could enhance clinical efficacy of the IP combination, which was considered a valid treatment option at the time of protocol initiation [19, 28, 29] . The ITP regimen, as used in the present study, resulted in an OR rate of 59% and median times of PFS and OS of 7.9 and 15.4 months, respectively. These outcomes are comparable with those we obtained in our previous phase II trial with the use of the same combination [23] . In the GOG 179 trial, the cisplatin-topotecan combination, which is currently considered an established treatment for women with advanced cervical cancer, yielded OR rate, median PFS and OS equal to 27%, 4.6 months and 9.4 months, respectively, for the investigational arm [22] . A potential reason for this discordance is the notably higher proportion of patients who had received prior cisplatin for radiosensitizing in the GOG trial (57%) compared with the current study (15%). Treatment outcomes for the control arm of our study were also comparable to those of previous reports [19] .
In our cohort, the addition of paclitaxel to the cisplatin and ifosfamide combination resulted in statistically significant Annals of Oncology original article increase in OR rate and PFS. However, since the current study was designed as a randomized phase II clinical trial, it can only allow the conclusion that the experimental arm merits to be further tested for this indication in larger phase III clinical trials that will compare the triplet with the currently established cisplatin-based combination with either topotecan or paclitaxel.
We observed a trend, albeit not statistically significant, for death (P = 0.099) for patients who relapsed within a previously irradiated field. In our previous phase II trial [23] , there was also a trend for higher response rate in patients with disease outside a radiation field (57% versus 28%; P = 0.1). We did not observe any significant effect of prior treatment with cisplatin-based chemoradiotherapy on PFS or OS in both treatment arms in multivariate analysis. The GOG 179 study reported for the experimental arm a HR of 0.87 versus 0.50 for PFS for patients who did versus those who did not receive prior cisplatin, suggesting a significantly less beneficial effect of chemotherapy in the former group [21] . Nevertheless, it should be noted that since only a small percentage (15%) of patients in our cohort had received cisplatin-based chemoradiotherapy as their initial treatment, platinum-free interval seems unlikely to influence patients' survival.
We were able to administer the chemotherapy regimens on an outpatient basis. The addition of paclitaxel to the IP combination did not increase hematologic or nonhematologic toxicity with the exception of neurotoxicity which was substantially increased as anticipated but moderate in severity in most cases. Neurotoxicity was a concern when the study was designed, especially for patients allocated to the ITP arm and those with prior cisplatin exposure. In our previous phase II studies, 44% of the patients treated with paclitaxel and cisplatin developed grade 1 or 2 neuropathy [23] . Other studies have reported grade 3 neurotoxicity rates from 8% to 20% with paclitaxel and cisplatin [30, 31] . In the current study, the rate of severe (grade > 2) neurotoxicity was higher in the ITP arm (4% versus 0%). Alternative strategies such as the separation of paclitaxel and cisplatin administration in two consecutive days as it was used in the present study or the substitution of cisplatin with carboplatin could be evaluated.
With the routine use of G-CSF, grade 3 or 4 neutropenia was observed in 28% of patients in our study while neutropenic infection was documented in 13%. Since a substantial proportion of our patients were expected to have received pelvic radiation, we decided to administer a hematopoietic growth factor in both arms to avoid dose reductions due to neutropenia. Importantly, none of the 130 deaths recorded was associated with treatment-related toxicity.
In conclusion, the current study shows that the addition of paclitaxel to the cisplatin-ifosfamide combination leads to a significant improvement in response rate and PFS at the cost of a modest increase in neurotoxicity. Recently reported results from the large randomized GOG 204 trial that compared four cisplatin-based doublets in advanced cervical cancer indicated that the paclitaxel-cisplatin combination should represent the control arm for future randomized phase III trials [32] . Therefore, the ITP regimen merits further investigation that will compare the triplet with the current, standard combination of cisplatin with paclitaxel. Should these results be confirmed, the ITP regimen could represent an alternative to current therapy in selected patients.
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